Pregnant women’s attitudes about topical microbicides for the prevention and treatment of bacterial vaginosis during pregnancy

Marina Catallozzi, Lauren Dapena Fraiz, Katharine M. Hargreaves, Gregory Zimet, Lawrence R. Stanberry, Adam J. Ratner, Shari E. Gelber, Susan L. Rosenthal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We sought to understand pregnant women’s product preference and likelihood of use of topical microbicides for bacterial vaginosis (BV) prevention and treatment. Pregnant women (N = 196) in a obstetrics clinic completed a survey between June 2014 and January 2015 about vaginal product use for BV. This cross-sectional study explored product preferences, likelihood of product use for BV management and father of the baby (FOB) involvement. Most participants were under 30 (68%) and underrepresented minorities (47% Hispanic, 21% African-American). Most women preferred the gel (69%). Only 30% were likely to use either product for prevention of BV; 76% if high risk for BV; 83% treatment of BV. Anticipated FOB involvement in decision-making included that 46% would ask his opinion, 38% would inform him of the decision and 7% would need approval. Most (87%) would ask the FOB for reminders and 66% for insertion help. Those under 30 were more likely to agree to ask the FOB for reminders (p < 0.01) and insertion help (p = 0.05). African-American women were less likely to have their FOB help with insertion (p < 0.01). Product preferences may be less critical than risk perception. Involvement of the FOB in decision-making may be vital.

Original languageEnglish (US)
Pages (from-to)881-886
Number of pages6
JournalInternational Journal of STD and AIDS
Volume28
Issue number9
DOIs
StatePublished - Aug 1 2017

Fingerprint

Bacterial Vaginosis
Local Anti-Infective Agents
Fathers
Pregnant Women
Pregnancy
African Americans
Decision Making
Therapeutics
Hispanic Americans
Obstetrics
Cross-Sectional Studies
Gels

Keywords

  • prevention
  • treatment
  • Women

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pregnant women’s attitudes about topical microbicides for the prevention and treatment of bacterial vaginosis during pregnancy. / Catallozzi, Marina; Fraiz, Lauren Dapena; Hargreaves, Katharine M.; Zimet, Gregory; Stanberry, Lawrence R.; Ratner, Adam J.; Gelber, Shari E.; Rosenthal, Susan L.

In: International Journal of STD and AIDS, Vol. 28, No. 9, 01.08.2017, p. 881-886.

Research output: Contribution to journalArticle

Catallozzi, Marina ; Fraiz, Lauren Dapena ; Hargreaves, Katharine M. ; Zimet, Gregory ; Stanberry, Lawrence R. ; Ratner, Adam J. ; Gelber, Shari E. ; Rosenthal, Susan L. / Pregnant women’s attitudes about topical microbicides for the prevention and treatment of bacterial vaginosis during pregnancy. In: International Journal of STD and AIDS. 2017 ; Vol. 28, No. 9. pp. 881-886.
@article{df6f62f27e2642768482ee5b6e8de202,
title = "Pregnant women’s attitudes about topical microbicides for the prevention and treatment of bacterial vaginosis during pregnancy",
abstract = "We sought to understand pregnant women’s product preference and likelihood of use of topical microbicides for bacterial vaginosis (BV) prevention and treatment. Pregnant women (N = 196) in a obstetrics clinic completed a survey between June 2014 and January 2015 about vaginal product use for BV. This cross-sectional study explored product preferences, likelihood of product use for BV management and father of the baby (FOB) involvement. Most participants were under 30 (68{\%}) and underrepresented minorities (47{\%} Hispanic, 21{\%} African-American). Most women preferred the gel (69{\%}). Only 30{\%} were likely to use either product for prevention of BV; 76{\%} if high risk for BV; 83{\%} treatment of BV. Anticipated FOB involvement in decision-making included that 46{\%} would ask his opinion, 38{\%} would inform him of the decision and 7{\%} would need approval. Most (87{\%}) would ask the FOB for reminders and 66{\%} for insertion help. Those under 30 were more likely to agree to ask the FOB for reminders (p < 0.01) and insertion help (p = 0.05). African-American women were less likely to have their FOB help with insertion (p < 0.01). Product preferences may be less critical than risk perception. Involvement of the FOB in decision-making may be vital.",
keywords = "prevention, treatment, Women",
author = "Marina Catallozzi and Fraiz, {Lauren Dapena} and Hargreaves, {Katharine M.} and Gregory Zimet and Stanberry, {Lawrence R.} and Ratner, {Adam J.} and Gelber, {Shari E.} and Rosenthal, {Susan L.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1177/0956462416679067",
language = "English (US)",
volume = "28",
pages = "881--886",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - Pregnant women’s attitudes about topical microbicides for the prevention and treatment of bacterial vaginosis during pregnancy

AU - Catallozzi, Marina

AU - Fraiz, Lauren Dapena

AU - Hargreaves, Katharine M.

AU - Zimet, Gregory

AU - Stanberry, Lawrence R.

AU - Ratner, Adam J.

AU - Gelber, Shari E.

AU - Rosenthal, Susan L.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - We sought to understand pregnant women’s product preference and likelihood of use of topical microbicides for bacterial vaginosis (BV) prevention and treatment. Pregnant women (N = 196) in a obstetrics clinic completed a survey between June 2014 and January 2015 about vaginal product use for BV. This cross-sectional study explored product preferences, likelihood of product use for BV management and father of the baby (FOB) involvement. Most participants were under 30 (68%) and underrepresented minorities (47% Hispanic, 21% African-American). Most women preferred the gel (69%). Only 30% were likely to use either product for prevention of BV; 76% if high risk for BV; 83% treatment of BV. Anticipated FOB involvement in decision-making included that 46% would ask his opinion, 38% would inform him of the decision and 7% would need approval. Most (87%) would ask the FOB for reminders and 66% for insertion help. Those under 30 were more likely to agree to ask the FOB for reminders (p < 0.01) and insertion help (p = 0.05). African-American women were less likely to have their FOB help with insertion (p < 0.01). Product preferences may be less critical than risk perception. Involvement of the FOB in decision-making may be vital.

AB - We sought to understand pregnant women’s product preference and likelihood of use of topical microbicides for bacterial vaginosis (BV) prevention and treatment. Pregnant women (N = 196) in a obstetrics clinic completed a survey between June 2014 and January 2015 about vaginal product use for BV. This cross-sectional study explored product preferences, likelihood of product use for BV management and father of the baby (FOB) involvement. Most participants were under 30 (68%) and underrepresented minorities (47% Hispanic, 21% African-American). Most women preferred the gel (69%). Only 30% were likely to use either product for prevention of BV; 76% if high risk for BV; 83% treatment of BV. Anticipated FOB involvement in decision-making included that 46% would ask his opinion, 38% would inform him of the decision and 7% would need approval. Most (87%) would ask the FOB for reminders and 66% for insertion help. Those under 30 were more likely to agree to ask the FOB for reminders (p < 0.01) and insertion help (p = 0.05). African-American women were less likely to have their FOB help with insertion (p < 0.01). Product preferences may be less critical than risk perception. Involvement of the FOB in decision-making may be vital.

KW - prevention

KW - treatment

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85023752379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023752379&partnerID=8YFLogxK

U2 - 10.1177/0956462416679067

DO - 10.1177/0956462416679067

M3 - Article

VL - 28

SP - 881

EP - 886

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 9

ER -